Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TPH1 | P17752 | 20/20 | 0.63 |
| ▸ | TPH2 | Q8IWU9 | 10/20 | 0.60 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | CCKAR | P32238 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | DRD3 | P35462 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL307950 | 1.00 | TPH1 (0.63) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL307732 | 0.89 | TPH1 (0.59) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL3682569 | 0.89 | TPH1 (0.59) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL871286 | 0.88 | TPH1 (0.57) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL869664 | 0.87 | TPH1 (0.58) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL870638 | 0.87 | TPH1 (0.62) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL14910945 | 0.86 | TPH1 (0.53) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL870175 | 0.86 | TPH1 (0.53) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL609700 | 0.85 | TPH1 (0.55) | TPH1TPH2F2ESR1ADORA3 | |
| SCHEMBL869663 | 0.85 | TPH1 (0.67) | TPH1TPH2F2ESR1ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2386547-B1 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2018-06-20 | — | — | EP | disclosed |
| EP-2386547-B1 | Multicyclic amino acid derivatives and methods of their use | LEXICON PHARMACEUTICALS INC (US) | 2018-06-20 | — | — | EP | disclosed |
| CN-103265495-B | Multicyclic amino acid derivatives and using method thereof | 莱西肯医药有限公司 | 2016-11-16 | — | — | CN | disclosed |
| US-8629156-B2 | Tryptophan hydroxylase inhibitors | LEXICON PHARMACEUTICALS, INC. (US) | 2014-01-14 | — | — | US | disclosed |
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | LEXICON PHARMACEUTICALS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130137635-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | LEXICON PHARMACEUTICALS, INC. (US) | 2013-05-30 | — | — | US | disclosed |
| US-8410121-B2 | Methods of treating pulmonary hypertension | LEXICON PHARMACEUTICALS, INC. (US) | 2013-04-02 | — | — | US | disclosed |
| EP-2533778-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | Lexicon Pharmaceuticals, Inc. (US) | 2012-12-19 | — | — | EP | disclosed |
| US-20120316171-A1 | Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer | LEXICON PHARMACEUTICALS, INC. | 2012-12-13 | — | — | US | disclosed |
| EP-1984344-B1 | MULTICYCLIC AMINO ACID DERIVATIVES AND METHODS OF THEIR USE | LEXICON PHARMACEUTICALS INC (US) | 2012-09-26 | — | — | EP | disclosed |
| EP-2170306-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | Lexicon Pharmaceuticals, Inc. (US) | 2010-04-07 | — | — | EP | disclosed |
| US-20090054308-A1 | Methods and Compositions for Treating Pulmonary Hypertension and Related Diseases and Disorders | TERSERA THERAPEUTICS LLC | 2009-02-26 | — | — | US | disclosed |
| US-20090029993-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | LEXICON PHARMACEUTICALS, INC. | 2009-01-29 | — | — | US | disclosed |
| WO-2009014972-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | LEXICON PHARMACEUTICALS, INC. (US) | 2009-01-29 | — | — | WO | disclosed |
| WO-2009009561-A1 | METHODS AND COMPOSITIONS FOR TREATING PULMONARY HYPERTENSION AND RELATED DISEASES AND DISORDERS | LEXICON PHARMACEUTICALS, INC. (US) | 2009-01-15 | — | — | WO | disclosed |
| US-20090005381-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | LEXICON PHARMACEUTICALS, INC. | 2009-01-01 | — | — | US | disclosed |
| US-20090005382-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | TERSERA THERAPEUTICS LLC | 2009-01-01 | — | — | US | disclosed |
| WO-2009002964-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | LEXICON PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009002970-A1 | COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | LEXICON PHARMACEUTICALS, INC. (US) | 2008-12-31 | — | — | WO | disclosed |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | TERSERA THERAPEUTICS LLC | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090054308-A1 | Methods and Compositions for Treating Pulmonary Hypertension and Related Diseases and Disorders | TPH1, PAH, TPH2 | TPH1 1/4885TPH2 3/4885F2 985/4885 |
| US-20130274261-A1 | METHODS FOR TREATING PULMONARY HYPERTENSION | TPH1, TPH2, PTGIS | TPH1 1/4885TPH2 2/4885F2 1046/4885 |
| US-20120316171-A1 | Tryptophan Hydroxylase Inhibitors for the Treatment of Cancer | TPH1, TPH2, HNMT | TPH1 1/4885TPH2 2/4885F2 4527/4885 |
| US-20070191370-A1 | Multicyclic amino acid derivatives and methods of their use | AADAT, HNMT, TPH1 | TPH1 3/4885TPH2 4/4885F2 808/4885 |
| US-20130137635-A1 | TRYPTOPHAN HYDROXYLASE INHIBITORS FOR THE TREATMENT OF METASTATIC BONE DISEASE | TPH1, TPH2, IDO1 | TPH1 1/4885TPH2 2/4885F2 4049/4885 |
| US-20090005381-A1 | METHODS OF TREATING SEROTONIN-MEDIATED DISEASES AND DISORDERS | TPH1, TPH2, HNMT | TPH1 1/4885TPH2 2/4885F2 2242/4885 |
| US-20090029993-A1 | METHODS OF AFFECTING GASTROINTESTINAL TRANSIT AND GASTRIC EMPTYING, AND COMPOUNDS USEFUL THEREIN | TPH1, TPH2, HNMT | TPH1 1/4885TPH2 2/4885F2 1080/4885 |
| US-20090005382-A1 | METHODS OF USING AND COMPOSITIONS COMPRISING TRYPTOPHAN HYDROXYLASE INHIBITORS | TPH1, TPH2, MAOB | TPH1 1/4885TPH2 2/4885F2 2409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.